Current Opinion in Investigational Drugs 2004-09-01

ETC-588 (Pfizer).

Sheila A Doggrell

Index: Curr. Opin. Investig. Drugs 5(9) , 993-9, (2004)

Full Text: HTML

Abstract

Pfizer, following its acquisition of Esperion Therapeutics in the first quarter of 2004, is developing ETC-588 as a potential acute treatment for ischemia caused by atherosclerosis. Enrollment in phase II trials in patients with acute coronary syndrome is complete.

Related Compounds

Related Articles:

Barotropic and thermotropic bilayer phase behavior of positional isomers of unsaturated mixed-chain phosphatidylcholines.

2009-05-01

[Biochim. Biophys. Acta 1788(5) , 1056-63, (2009)]

Bridging the gap between molecular descriptors and mechanism: Cases studies by molecular dynamics simulations

2009-01-01

[J. Mol. Graph. Model. 27(7) , 829-35, (2009)]

The cytoplasmic region of mouse Fc gamma RIIb1, but not Fc gamma RIIb2, binds phospholipid membranes.

1999-02-16

[Biochemistry 38(7) , 2102-9, (1999)]

Immobilized liposome chromatography for studies of protein-membrane interactions and refolding of denatured bovine carbonic anhydrase.

1998-08-07

[J. Chromatogr. B. Biomed. Sci. Appl. 712(1-2) , 59-71, (1998)]

Fourier transform infrared spectroscopy as a probe for the study of the hydration of lipid self-assemblies. I. Methodology and general phenomena.

1998-01-01

[Biospectroscopy 4(4) , 267-80, (1998)]

More Articles...